Eupraxia Pharmaceuticals (EPRX) Competitors $5.35 -0.24 (-4.31%) Closing price 07/15/2025 03:55 PM EasternExtended Trading$5.69 +0.34 (+6.36%) As of 07/15/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. CRMD, IMNM, SNDX, KALV, REPL, XERS, VIR, GYRE, NUVB, and SANAShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include CorMedix (CRMD), Immunome (IMNM), Syndax Pharmaceuticals (SNDX), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Xeris Biopharma (XERS), Vir Biotechnology (VIR), Gyre Therapeutics (GYRE), Nuvation Bio (NUVB), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors CorMedix Immunome Syndax Pharmaceuticals KalVista Pharmaceuticals Replimune Group Xeris Biopharma Vir Biotechnology Gyre Therapeutics Nuvation Bio Sana Biotechnology CorMedix (NASDAQ:CRMD) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the media prefer CRMD or EPRX? In the previous week, CorMedix had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 5 mentions for CorMedix and 2 mentions for Eupraxia Pharmaceuticals. CorMedix's average media sentiment score of 0.94 beat Eupraxia Pharmaceuticals' score of 0.62 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CRMD or EPRX? CorMedix has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Which has higher valuation & earnings, CRMD or EPRX? CorMedix has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M17.74-$17.93M$0.2251.68Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.04 Is CRMD or EPRX more profitable? CorMedix has a net margin of 20.81% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 22.57% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CorMedix20.81% 22.57% 17.02% Eupraxia Pharmaceuticals N/A -367.73%-112.23% Do analysts rate CRMD or EPRX? CorMedix currently has a consensus price target of $17.14, indicating a potential upside of 50.77%. Eupraxia Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 105.65%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders & institutionals believe in CRMD or EPRX? 34.2% of CorMedix shares are owned by institutional investors. 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryCorMedix beats Eupraxia Pharmaceuticals on 13 of the 15 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$201M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-7.0420.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / BookN/A7.568.145.54Net Income-$25.50M-$55.11M$3.24B$257.73M7 Day Performance-2.03%3.81%0.18%-0.08%1 Month Performance28.27%11.60%5.96%8.09%1 Year Performance88.35%-2.11%26.24%13.02% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.3855 of 5 stars$5.35-4.3%$11.00+105.6%+99.6%$201MN/A-7.0429Positive NewsGap UpCRMDCorMedix2.6766 of 5 stars$11.28-1.2%$17.14+52.0%+132.0%$774.56M$43.47M51.2830IMNMImmunome1.9992 of 5 stars$8.55-1.6%$23.33+172.9%-40.7%$756.14M$9.04M-2.6940Positive NewsSNDXSyndax Pharmaceuticals3.0714 of 5 stars$8.75+0.2%$35.80+309.1%-62.2%$751.19M$23.68M-2.27110News CoverageAnalyst ForecastKALVKalVista Pharmaceuticals4.036 of 5 stars$14.95-0.7%$26.29+75.8%+1.4%$748.72MN/A-4.02100Earnings ReportAnalyst RevisionGap UpHigh Trading VolumeREPLReplimune Group4.123 of 5 stars$9.34-3.2%$20.83+123.1%+14.7%$743.89MN/A-3.04210News CoverageOptions VolumeXERSXeris Biopharma3.9403 of 5 stars$4.77+1.5%$6.25+31.0%+113.3%$735.01M$203.07M-15.90290VIRVir Biotechnology3.5594 of 5 stars$5.30+0.6%$32.86+519.9%-44.6%$728.51M$74.21M-1.26580GYREGyre Therapeutics0.1238 of 5 stars$8.12+6.6%N/A-48.7%$714.43M$105.76M406.2040News CoverageNUVBNuvation Bio3.1281 of 5 stars$2.05-1.4%$7.17+249.6%-37.9%$707.75M$7.87M-0.8760SANASana Biotechnology3.2341 of 5 stars$3.89+25.5%$9.17+135.6%-34.3%$698.98MN/A-4.42380High Trading Volume Related Companies and Tools Related Companies CorMedix Competitors Immunome Competitors Syndax Pharmaceuticals Competitors KalVista Pharmaceuticals Competitors Replimune Group Competitors Xeris Biopharma Competitors Vir Biotechnology Competitors Gyre Therapeutics Competitors Nuvation Bio Competitors Sana Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
